Skip to main
BSX
BSX logo

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific demonstrates a strong growth outlook, with the Watchman product line projected to achieve a compound annual growth rate (CAGR) of 20% over the long-range plan (LRP), supported by potential positive data from the Champion trial. The company's electrophysiology (EP) revenue is expected to rise from an estimated $3.3 billion in 2025 to approximately $6 billion by 2028, reflecting a CAGR of about 22%, indicating robust demand for its innovations. Additionally, Boston Scientific anticipates continued mid-teens revenue growth from the Chinese market, bolstering its international sales, which already constitute roughly 36% of total revenue.

Bears say

Boston Scientific faces several fundamental challenges that contribute to a negative outlook on its stock. Key risks include potential slowdowns in innovation, increased competition in core markets, and uncertainty surrounding the success of ongoing and future product launches, which could adversely affect revenue growth. Additionally, the company may encounter integration risks from mergers and acquisitions, difficulties in managing existing and future debt, and challenges in expanding internationally, further exacerbated by the possibility of litigation risks.

Boston Scientific (BSX) has been analyzed by 22 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 22 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $121.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $121.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.